SEBI Reg. Investment Advisor

Download App
Help Center Pricing
Money Works 4 Me Logo MoneyWorks4Me
Login Get Free Account
Sign Up

MoneyWorks4Me

Log In Sign Up Schedule Free 15‑min Call
Login Get Free Account
Sign Up

INVESTMENT INSIGHTS

Check Before You Invest : Hester Biosciences Ltd

BSE: 524669 NSE: HESTERBIO ISIN: INE782E01017
  |   Sector:  Healthcare   |   Industry:  Pharmaceuticals & Drugs

Snapshot

Q.1 Which industry/sub-sector does Hester Biosciences Ltd belong to?
Hester Biosciences Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.
Q.2 Is Hester Biosciences Ltd a good quality company?
Hester Biosciences Ltd is a good quality company, based on a consistently good 10 year financial track record.
Q.3 Is Hester Biosciences Ltd undervalued or overvalued?
Hester Biosciences Ltd appears Undervalued, as its key valuation ratios are below with their past averages.
Q.4 Is Hester Biosciences Ltd a good buy now?
Hester Biosciences Ltd is a neutral opportunity now, based on stable price trend analysis suggesting prices may move sideways. However, you need to check its quality and valuation before making a decision

Performance Analysis

Q.1 Revenue growth of Hester Biosciences Ltd?
Hester Biosciences Ltd revenue growth is 0.5% for FY-2025 , which is below its 5 year CAGR of 11.1% , indicating slower growth.
Q.2 Gross Profit margin of Hester Biosciences Ltd?
Hester Biosciences Ltd Gross profit margin which is the profit after deduction of direct costs, is 17.6% for FY-2025 , which is below its 5 year median of 21% , indicating decreasing margins.
Q.3 Operating Profit Margin of Hester Biosciences Ltd?
Hester Biosciences Ltd Operating Profit Margin which is the profit after deduction of all operating costs, is 17.95% for FY-2025 , which is below its 5 year median of 21.53% indicating decreasing margins.
Q.4 Net Profit Margin of Hester Biosciences Ltd?
Hester Biosciences Ltd Net Profit Margin is 11.12% for FY-2025 , is below with its 5 year median of 12.73%, indicating decreasing margins.
Current Level Historic Median
Gross Profit Margin 17.6 21
Operating Profit Margin 17.95 21.53
Net Profit Margin 11.12 12.73
Q.5 Return on Asset of Hester Biosciences Ltd?
Hester Biosciences Ltd Return on Asset is 5.81%, which is below its 5 year historical median of 6.67%, indicating deteriorated asset utilization efficiency.
Q.6 Return on Equity (ROE) of Hester Biosciences Ltd?
Hester Biosciences Ltd Return on equity is 9.77% for FY-2025 , which is below its historical median of 11.53%, indicating the business is making worse use of its shareholders capital.
Q.7 Return on capital employed (ROCE) of Hester Biosciences Ltd?
Hester Biosciences Ltd Return on capital employed is 10.59% for FY-2025 , which is below its estimated weighted average cost of capital(WACC) 14%, indicating value preservation.
Q.8 Cash conversion cycle of Hester Biosciences Ltd?
Hester Biosciences Ltd Cash conversion cycle is 131 days, below its historical median of 152 days, indicating improved working capital management. However, you need to compare this with its peers in the industry.
Current Level Historic Median
Asset Turnover 0.52 0.53
ROE 9.77 11.53
ROCE 10.59 11.91
Cash Conversion Cycle 131 days 152 days
Q.9 Debt to Equity ratio of Hester Biosciences Ltd?
Hester Biosciences Ltd Debt-to-Equity ratio is 0.31 , which is above with the industry average of 0.15 , indicating higher debt levels in the industry.
Q.10 Debt to cash flow from operations of Hester Biosciences Ltd?
Hester Biosciences Ltd Debt to cash flow from operations is 1.63 , which is at a moderate level.

Ownership & governance

Q.1 Promoter shareholding and pledge status of Hester Biosciences Ltd?
Promoters hold 53.73% of the Hester Biosciences Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Peer comparison (industry-wise, mcap)

Q.1 Revenue growth of Hester Biosciences Ltd vs industry peers?
Hester Biosciences Ltd revenue CAGR is 11.08% , compared to the industry median CAGR of 5.54% , indicating faster growth and gaining its market share.
Profit Metrics
Current Level Industry Median
Revenue 286.5 137.1
Gross Profit 50.3 15.1
Operating Profit 51 16
Net Profit 32 5.6
Operating Efficiency
Current Level Industry Median
Asset Turnover 0.52 0.8
ROE 9.77 8.91
ROCE 10.59 11.59
Cash Conversion Cycle (days) 130.98 76

Valuation & price assessment

Q.1 Stock return of Hester Biosciences Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 10.7% based on the current price.
Q.2 What return has the stock given over the last decade?
9Y 5Y 3Y 1Y
Share Price 10.7% -8.8% -6.3% -16%
Q.3 Valuation ratios of Hester Biosciences Ltd vs historical?
The current P/E is lower that its historical median.
Q.4 How do the current valuation ratios measure up against the historic numbers and the current industry numbers?
Valuation Ratios Current Historic Median Industry Median
Price to Earnings 35.42 44.65 40.28
Price to Book 3.49 6.16 2.77
Price to Sales 4.55 7.86 2.65
EV to EBITDA 22.82 26.19 15.67

Check more companies

1. Ajanta Pharma
2. JB Chem & Pharma
3. Emcure Pharma
4. Gland Pharma
5. Wockhardt
6. Pfizer
7. Astrazeneca Pharma I
8. Sai Life Sciences
9. Natco Pharma
10. Eris Lifesciences
2026 ©The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me® is a registered trademark of The Alchemists Ark Pvt. Ltd.

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×